SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending due to an earnings "double beat" and positive AI demand commentary, fueling optimism and sending shares higher after hours. The community is celebrating the results, anticipating further gains, and some speculate about government influence and potential short squeezes. Discussions include targets, the CEO's performance, and the broader implications for the semiconductor sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amid speculation and conflicting reports about potential government equity stakes in quantum computing firms, driving volatility and high trading volume. The community is debating the validity and impact of the rumored deal, with some seeing it as a validation of the sector while others believe it's a pump and dump scheme. Broader discussions include the long-term potential of quantum computing and its significance in the global technology race.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford ($F) is trending as investors react to potential tariff relief and strong Q3 sales figures, including a surge in EV sales, before the EV tax credit expires. Community members are discussing whether Ford can sustain this momentum, especially with a focus on management's plans and the potential for a breakout above the $12.50 resistance level. Some are also closely monitoring a news report regarding potential changes coming Monday.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor (DECK) is experiencing share price volatility despite a recent earnings beat, leading to community discussion about potential reasons for the disconnect, including concerns about future guidance. Some traders point to significant call option activity, while others speculate on the impact of tariffs and broader retail sector trends. Despite strong brand performance with Hoka and UGG, investors are debating whether the current price represents a buying opportunity or reflects deeper concerns.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont Corp ($NEM) is trending after posting strong quarterly earnings, exceeding analysts' estimates, which the community is calling a major beat. Bullish sentiment is growing as investors discuss cost-saving initiatives and rising gold prices potentially driving the stock higher. However, some traders are cautious, anticipating short-term pullbacks and profit-taking despite the positive results.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen is trending following news of a multi-billion dollar network expansion aimed at meeting growing AI demand. Community members are discussing the potential for increased revenue, key partnerships, and upcoming earnings while also debating the company's debt and long-term growth strategy. Some are speculating about new deals and the possibility of a short squeeze, while others highlight the company's strategic importance in the AI infrastructure buildout.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc is trending as investors discuss the potential impact of CFO Mala Murthy's departure, with many viewing it as a positive catalyst for the stock. Community members are also focused on upcoming earnings and the company's AI applications, speculating on a possible short squeeze. Overall sentiment suggests optimism about a turnaround, with some drawing comparisons to other heavily shorted stocks.

Above Food Ingredients, Inc. engages in operating its subsidiaries, Bite Acquisition Corp. (Bite) and Above Food Corp. (Above Food). The Bite is a blank check company that affects a merger, stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Above Food is an ingredient company that provides food products and brands. The company was founded by Lionel Kambeitz on April 18, 2023 and is headquartered in Regina, Canada.

Above Food Ingredients Inc.

ABVE is trending as investors eagerly await news related to the Palm Global merger and the audit results, with some speculating about potential catalysts at upcoming conferences. Community members are expressing both excitement and impatience, while also debating short selling activity and potential price targets. The anticipation surrounds the company's transition towards real-world asset tokenization and stablecoin issuance.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is trending as investors discuss potential government contracts and insider trading after significant call option sweeps, specifically for the $27 strike price. Community members speculate about upcoming news related to rare earth minerals and uranium, driven by geopolitical tensions and a focus on domestic supply chains. While some traders express caution and highlight algorithmic trading patterns, bullish sentiment remains strong due to the company's strategic positioning in the sector.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as discussions swirl around potential government equity stakes in quantum computing firms, highlighted in a recent TechSpot article. The community is debating the implications of government involvement, with some seeing it as a bullish signal for the sector and others expressing skepticism, particularly regarding the details and financing of any potential deals. Amidst this, QUBT's relatively low market cap and substantial cash reserves are also points of focus.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy...

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates

Repare Therapeutics (RPTX) delivered earnings and revenue surprises of +30.36% and -95.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics saw its stock climb in after-hours trading Tuesday after disclosing a global licensing deal with Switzerland-based Debiopharm International for lunresertib, a first-in-class PKMYT1 inhibitor aimed at treating hard-to-tackle solid tumors.The agreement gives Repare a $10 million upfront boost, with the potential to bring in up to $257 million more through clinical, regulatory, and commercial milestones, including $5 million in possible near-term payouts.&nbsp;Repare will also earn single-digit royalties on future global net sales.<a href="https://stocktwits.com/symbol/RPTX">RPTX’s stock</a> closed Monday down 8.9% at $1.43, but rebounded 22.4% in after-hours trading to $1.75.The agreement builds on an existing collaboration between the two companies that explored the synergy of lunresertib with Debiopharm’s Debio 0123, a selective WEE1 inhibitor.&nbsp;As part of the deal, Debiopharm will take over sponsorship of the Mythic trial and assume all development activities related to lunresertib moving forward.Repare remains on track to report initial data from two ongoing Phase 1 trials—the Lions trial for its PLK4 inhibitor RP-1664 and the Polar trial for its Polθ ATPase inhibitor RP-3467—in the second half of 2025.As of March 31, Repare had $124.2 million in cash and marketable securities on hand, which it says should be enough to fund its operations through 2027.&nbsp;The company reported a net loss of $0.71 per share in the first quarter, swinging from a profit of $0.30 per share in the same period last year.&nbsp;Repare has said it continues to explore strategic alternatives across its pipeline, including out-licensing and partnerships.On Stocktwits, retail sentiment for RPTX was ‘extremely bullish’ amid ‘extremely high’ message volume.One Stocktwits user expressed optimism about their position in the stock, noting an entry point at $1.62 with 10,000 shares and indicating confidence heading into the pre-market session.&nbsp;<stembedurl>https://stocktwits.com/TheThroatSlasher/message/621090644</stembedurl>Another user encouraged buying, citing the stock’s after-hours gain.<stembedurl>https://stocktwits.com/Eelmm842/message/621076455</stembedurl>RPTX’s stock has risen 8.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Repare Therapeutics (RPTX) disclosed a global licensing deal with Switzerland-based Debiopharm International. (Photo credit: Getty Images)

Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In

Repare Therapeutics saw its stock climb in after-hours trading Tuesday after disclosing a global licensing deal with Switzerland-based Debiopharm International for lunresertib

Equity

The deal builds on an existing collaboration around lunresertib and hands development control to Debiopharm, allowing Repare to focus on its Phase 1 trials for RP-1664 and RP-3467.

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a re-alignment of resources and a re-prioritization of its...

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options PR Newswire VANCOUVER, BC, Dec. 23, 2024 Issued on...

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive data from its MYTHIC Phase 1 gynecologic expansion...

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the...

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been...

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2024...

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data highlighting the benefits of its individualized...

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

RPTX
Repare Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RPTX News

RPTXRepare Therapeutics Inc